Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats

Chirality

Volumn 15, Issue 5, 2003, Pages 423-428

  Nagao, Tomoaki ^a   Tanino, Tadatoshi ^a   Iwaki, Masahiro ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

2 arylpropionate nonsteroidal antiinflammatory drug; Adjuvant induced arthritis; Covalent binding; Flurbiprofen; Glucuronide; Stereoselective pharmacokinetics

Indexed keywords

CYTOCHROME P450; ETODOLAC; FLURBIPROFEN; GLUCURONIDE; NAPROXEN; PLASMA PROTEIN; RAC PROTEIN; SERUM ALBUMIN;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; ENANTIOMER; GLUCURONIDATION; LIVER MICROSOME; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; STEREOCHEMISTRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BILE; BLOOD PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; FLURBIPROFEN; GLUCURONIDES; MALE; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 0037276097     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10227     Document Type: Article

References (29)

1. Zia-Amirhosseini P, Harris RH, Brodsky FM, Benet LZ. Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nature Med 1995;1:2-5.
2. Castro EF, Soraci AL, Franci R, Fogel FA, Tapia MO. Disposition of suprofen enantiomers in the cat. Vet J 2001;162:38-43.
3. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995;28:100-114.
4. Brocks DR, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet 1994;26:259-274.
5. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990;19:197-217.
6. Jamali F, Berry BW, Tehrani MR, Russell AS. Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 1988;77: 666-669.
7. Abas A, Meffin PJ. Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. IV. Ketoprofen disposition. J Pharmacol Exp Ther 1986;240:637-641.
8. Foster RT, Jamali F, Russel AS, Alballa SR. Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. J Pharm Sci 1988;77:70-73.
9. Pedrazzini S, Angelis MD, Muciaccia WZ, Sacchi C, Forgione A. Stereochemical pharmacokinetics of the 2-arylpropionic acid non-steroidal antiinflammatory drug flunoxaprofen in rats and in man. Arzneim-Forsh/Drug Res 1988;38:1170-1175.
10. Walker KA, Barber HE, Hawksworth GM. Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Drug Metab Dispos 1986;14:482-486.
11. Piquette-Miller M, Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen treated and untreated adjuvant arthritis. Drug Metab Dispos 1995;23: 240-245.
12. Piquette-Miller M, Jamali F. Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions 1992;37:290-296.
13. Pollock SH, Matthews HW, D'Souza MJ. Pharmacokinetic analysis of cyclosporine in adjuvant arthritic rats. Drug Metab Dispos 1989;17: 595-599.
14. Meunier CJ, Verbeeck RK. Glucuronidation kinetics of R,S-ketoprofen in adjuvant-induced arthritic rats. Pharm Res 1999;16:1081-1086.
15. Bischer A, Zia-Amirhosseini P, Iwaki M, McDonagh AF, Benet LZ. Stereoselective binding properties of naproxen glucuronide diastereomers to proteins. J Pharmacokin Biopharm 1995;23:379-395.
16. Omura T, Sato R. Carbon monoxide-binding pigment of liver microsomes. I: Evidence for its hemoprotein nature. J Biol Chem 1964;239: 2370-2378.
17. Berry BW, Jamali F. Enantiomeric interaction of flurbiprofen in the rat. J Pharm Sci 1989;78:632-634.
18. Risdall PC, Adams SS, Crampton EL, Marchant B. The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica 1978;8:691-704.
19. Szpunar GL, Albert KS, Bole GG, Dreyfus JN, Lockwood GF, Wagner JG. Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. Biopharm Drug Dispos 1987;8:273-283.
20. Knadler MP, Brater DC, Hall SD. Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status. J Pharmacol Exp Ther 1989;249:378-385.
21. Meunier CJ, Verbeeck RK. Glucuronidation of R- and S-ketoprofen, acetaminophen, and diflunisal by liver microsomes of adjuvant-induced arthritic rats. Drug Metab Dispos 1999;27:26-31.
22. Hamdoune M, Mounie J, Magdalou J, Masmoudi T, Goudonnet H, Escousse A. Characterization of the in vitro glucuronidation of flurbiprofen enantiomers. Drug Metab Dispos 1995;23:343-348.
23. Ding A, Ojingwa JC, McDonagh AF, Burlingame AL, Benet LZ. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc Natl Acad Sci USA 1993;90:3797-3801.
24. Ding A, Zia-Amirhosseine P, McDonagh AF, Burlingame AL, Benet LZ, Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos 1995;23:369-376.
25. Smith PC, McDonaph AF, Benet LZ. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 1986;77:934-939.
26. Hyneck ML, Smith PC, Munafo A, McDonaph AF, Benet LZ. Disposition and irreversible plasma protein binding of tolmetin in humans. Clin Pharmacol Ther 1988;44:107-114.
27. Volland C, Sun H, Dammeyer J, Benet LZ. Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma proteins. Drug Metab Dispos 1991;19:1080-1086.
28. Iwakawa S, Spahn H, Benet LZ, Lin ET. Stereoselective binding of the glucuronide conjugates of carprofen enantiomers to human serum albumin. Biochem Pharmacol 1990;39:949-953.
29. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschen E, Lin ET. Predictability of the covalent binding of acidic drugs in man. Life Sci 1993;53:141-146.